House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices. “We’re working between the Commerce Committee and the Judiciary Committee on a compromise on what we call CREATES, which is getting the generics online faster after patents have expired, so I think there are things we can do in that area,” Ryan said, according to published reports, during an event hosted by a Washington, D.C. law firm. Among other provisions, the legislation would allow a generic drug manufacturer facing a sample-sharing delay tactic to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Earlier this year, AHA and more than 40 organizations urged Congress to pass the legislation calling it “a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year.”

Related News Articles

Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Chairperson's File
Public
One of the most rewarding parts of being an AHA member and serving on the board is building relationships with other leaders who share a passion for making…
Headline
The AHA Dec. 11 expressed support for the reintroduction of the Future Advancement of Academic Nursing, bicameral legislation that would increase nursing…
Headline
The Centers for Medicare & Medicaid Services released guidance Dec. 8 for states implementing Medicaid community engagement requirements outlined by the…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…
Headline
The Centers for Medicare & Medicaid Services Nov. 25 announced lower prices for 15 Medicare Part D drugs selected for the second cycle of negotiations…